Table 2.
Allele frequency and genotype distribution of the A1166C polymorphism of AT1R, n (%).
| Control subjects, n = 82 | COVID-19 patients |
||||
|---|---|---|---|---|---|
| Without oxygen therapy, n = 110 | Non-invasive oxygen therapy, n = 136 | Invasive oxygen therapy |
|||
| Total, n = 36 | Of them died, n = 12 | ||||
| Genotype Distribution, n (%) | |||||
| АА | 42 (51.2) | 56 (50.9) | 46 (33.8) | 10 (27.8) | 2 (16.7) |
| АС | 28 (34.1) | 36 (32.7) | 76 (55.9) | 16 (44.4) | 10 (83.3) |
| СС | 12 (14.7) | 18 (16.4) | 14 (10.3) | 10 (27.8) | 0 |
| P = 0.008 | P = 0.047 | ||||
| AC + CC | 40 (48.8) | 54 (49.1) | 90 (66.2) | 26 (72.2) | 10 (83.3) |
| p = 0.012 | p = 0.019 | p = 0.026 | |||
| OR = 2.05 | OR = 2.73 | OR = 5.25 | |||
| CI (1.17–3.60) | CI (1.17–6.38) | CI (1.08–25.46) | |||
| p1 = 0.007 | p1 = 0.016 | p1 = 0.025 | |||
| OR = 2.03 | OR = 2.70 | OR = 5.19 | |||
| CI (1.21–3.40) | CI (1.19–6.12) | CI (1.09–24.76) | |||
| Allele Frequency, n (%) | |||||
| А | 112 (68.3) | 148 (67.3) | 168 (61.8) | 36 (50.0) | 14 (58.3) |
| С | 52 (31.7) | 72 (32.7) | 104 (38.2) | 36 (50.0) | 10 (41.7) |
| p = 0.011 | |||||
| OR = 2.15 | |||||
| CI (1.22–3.80) | |||||
| p1 = 0.013 | |||||
| OR = 2.06 | |||||
| CI (1.20–3.53) | |||||
Note: p – comparison with control subjects; p1 – comparison with COVID-19 patients without oxygen therapy.